| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S15873 R65424 |
Dreier (Oxcarbazepine) (Epilepsy) (Controls exposed to LTG), 2023 | Autism spectrum disorder - Corresponding ICD-10 F-chapter - Up to 22 years of age | during pregnancy (anytime or not specified) | population based cohort propective | exposed to other treatment, sick excluded | Adjustment: No |
1.77 [1.15;2.73] C excluded (control group) |
31/1,460 64/5,288 | 95 | 1,460 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15874 R65439 |
Dreier (Oxcarbazepine) (Epilepsy) (Controls unexposed, sick), 2023 | Autism spectrum disorder - Corresponding ICD-10 F-chapter - Up to 22 years of age | during pregnancy (anytime or not specified) | population based cohort propective | unexposed, sick | Adjustment: Yes | 1.22 [0.80;1.87] | 31/1,460 323/22,203 | 354 | 1,460 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S10096 R46429 |
Coste (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2020 | Diagnosis Pervasive developmental disorders (F84) (mean age of 3.7 years old) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: Yes Controls: mixed indications |
2.00 [0.30;13.80] excluded (control group) |
1/143 11/2,916 | 12 | 143 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7808 R46430 |
Coste (Oxcarbazepine) (Controls unexposed, NOS), 2020 | Diagnosis Pervasive developmental disorders (F84)(mean age of 3.6 years old) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes | 1.70 [0.20;12.40] | 1/143 4,280/1,710,441 | 4,281 | 143 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9965 R46432 |
Bjørk (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2018 | Autistic traits at 18 months and/or at 36 months (M-CHAT <2/6 critical or <3/23 or SCQ >13) | during pregnancy (anytime or not specified) | population based cohort propective | exposed to other treatment, sick excluded | Adjustment: No |
0.66 [0.03;13.57] C excluded (control group) |
0/4 13/76 | 13 | 4 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9953 R46433 |
Bjørk (Oxcarbazepine) (Controls unexposed, disease free), 2018 | Autistic traits at 18 months and/or at 36 months (M-CHAT <2/6 critical or <3/23 or SCQ >13) | during pregnancy (anytime or not specified) | population based cohort propective | unexposed, disease free excluded | Adjustment: No |
1.42 [0.07;27.47] C excluded (control group) |
0/4 6,907/75,497 | 6,907 | 4 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S9967 R46434 |
Bjørk (Oxcarbazepine) (Controls unexposed, sick), 2018 | Autistic traits at 18 months and/or at 36 months (M-CHAT <2/6 critical or <3/23 or SCQ >13) | during pregnancy (anytime or not specified) | population based cohort propective | unexposed, sick | Adjustment: No | 1.27 [0.06;25.24] C | 0/4 27/272 | 27 | 4 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 3 studies | 1.24 [0.82;1.87] | 4,662 | 1,607 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Oxcarbazepine) (Epilepsy) (Controls unexposed, sick; 2: Oxcarbazepine) (Controls unexposed, NOS; 3: Oxcarbazepine) (Controls unexposed, sick;
Funnel plot not drawn. Less than 3 points.
Asymetry test p-value = NaN (by Egger's regression)
not enought points
Funnel plot not drawn. Less than 3 points.
excluded 9965, 9953, 10096, 15873